August 21, 2025Nature CommunicationsOpen Access

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Preclinical findings reveal AFM28's anti-leukemic activity in AML and MDS, indicating enhanced NK cell function.

AFM28 effectively eliminates CD123+ leukemic stem and progenitor cells, suggesting a new approach to treatment.
In vitro studies show AFM28 has superior activity compared to standard CD123-targeting antibodies against leukemic cells.
The bispecific engager triggers anti-leukemic responses, enhancing NK cell activity when combined with allogeneic cells.
Well-tolerated in models, AFM28 demonstrates its potential to improve long-term remissions and minimize relapse risks.

Schmitt et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark